The AI Capex Paragraph
Micron FY2026 revenue $133B (+256% YoY) with 85.86% gross margins; Nvidia data center revenue $89B (+117% YoY) versus AMD $6.7B; Stansberry Research: $4.5T AI data center buildout needs ~$1.7T annual revenue to break even, far above today’s ~$1T from hyperscalers; CoreWeave $104B backlog, 112% revenue growth, but $626M losses on $640M interest expense.
The Power Bottleneck
Liberty Energy deployed $1.5B capex for behind-the-meter generation; Fervo Energy’s geothermal Cape Station permitted for 2GW with Google PPAs; Bloom Energy claims its solid-oxide fuel cells would cut non-chip construction costs for a 1GW AI data center by $3.6B (27%) and 5-year ownership costs by $5.5B (9%); Nvidia plans full-scale 800V DC data-center production alongside its Kyber racks in 2027; Centrus Energy holds a $4.5B HALEU backlog through 2040, the only NRC-licensed US producer supplying SMR developers like Oklo and X-energy; NuScale holds the sole certified SMR design with TVA deployments negotiated.
Fixed Income’s Lost Safe-Haven Status
Bill Gross warns against longer-term bonds: $84T in government/mortgage/corporate debt, Fed at 100% debt-to-GDP peacetime peak; 10-year yields at 24-year highs (5.34%); hedge funds now hold 8.5% of Treasuries via basis trades that could unwind violently in risk-off; JPMorgan’s Dimon describes ‘tectonic plates’ — geopolitical conflict, high inflation, elevated leverage, stretched equity valuations; RBI likely hiking repo to 5.50% as Indian 10-year yields hit 7.21%; Indian banks face MTM losses on treasury portfolios as the 10-year benchmark rose 43.8 bps during Q2 to close at 7.19%; FCNR(B) inflows of $133B flatten headline deposit growth, but CASA dilution and MTM losses loom.
Healthcare’s Binary Catalysts
Eli Lilly’s retatrutide showed 28.3% weight loss vs Zepbound’s 20.2% — triple-hormone mechanism with sleep apnea benefit; Lilly plans to file for approval in Q1 2027; the global weight-loss market is projected to grow at a 27% CAGR through 2036; Pfizer faces patent cliffs on Ibrance/Eliquis/Prevnar 13 (one-third of revenue) with oncology pivot not paying off until 2029; CDMO sector (Laurus Labs +90%, Divi’s Labs) riding 7x market growth to $22-25B by 2035 on GLP-1 peptide outsourcing; Novo Nordisk shifting peptide production to CDMOs; Grail’s Galleri test nearing FDA approval but profitability not until 2032/33; Grail’s $1,000 test with 54.7% sensitivity for 12 deadliest cancers and 99.6% specificity.
India’s Structural Inflection
Jio Platforms IPO at $143-146B valuation (2.9% float, $3.8B raise) with 39% mobile share, 5G covering 268M users; GST 2.0 reforms easing compliance — centralized audits, ITC protection, arrest power removal, prosecution threshold raised to ₹5Cr; banking deposits/advances growing ~18% but FCNR(B) inflows ($133B) flatter headline numbers; CASA dilution and MTM losses on bond portfolios loom; IT services M&A wave (TCS/HCLTech/Wipro buying GCCs) offsetting 0.5-1% organic growth.
Consumer Durability Test
Nike revenue -4% YoY, China -22%, dividend payout 85.7% of net income with buybacks halted; McDonald’s -24% YTD, 50th consecutive dividend raise but Q2 revenue growth slowed to 3.7%, lost $310M from lower-income consumers; Monster Beverage’s flywheel sustaining 55.5% gross margins; Flipkart sellers doubled to 1.4M on zero-commission model.